About Us
Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential.
The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).
-
Regulatory January 29, 2026Vivesto carries out a directed share issue to guarantors in connection with the completed rights issue
-
Regulatory January 23, 2026Vivesto announces outcome of the rights issue
-
Regulatory January 2, 2026Vivesto publishes information document regarding the rights issue
Interim Report Q3 2025 (in Swedish)
Vivesto published its Q3 report for 2025 on November 20, 2025, at 08.00 am CET.